AU733621B2 - Novel compounds and compositions for treating diseases associated with tryptase activity - Google Patents

Novel compounds and compositions for treating diseases associated with tryptase activity Download PDF

Info

Publication number
AU733621B2
AU733621B2 AU39670/97A AU3967097A AU733621B2 AU 733621 B2 AU733621 B2 AU 733621B2 AU 39670/97 A AU39670/97 A AU 39670/97A AU 3967097 A AU3967097 A AU 3967097A AU 733621 B2 AU733621 B2 AU 733621B2
Authority
AU
Australia
Prior art keywords
alkylene
compound
formula
hetero
piperazinecarboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39670/97A
Other languages
English (en)
Other versions
AU3967097A (en
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Axys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals Inc filed Critical Axys Pharmaceuticals Inc
Publication of AU3967097A publication Critical patent/AU3967097A/en
Assigned to AXYS PHARMACEUTICALS, INC. reassignment AXYS PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: ARRIS PHARMACEUTICAL CORPORATION
Application granted granted Critical
Publication of AU733621B2 publication Critical patent/AU733621B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU39670/97A 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity Ceased AU733621B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US60/023139 1996-07-30
US89577297A 1997-07-17 1997-07-17
US08/895772 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
AU3967097A AU3967097A (en) 1998-02-20
AU733621B2 true AU733621B2 (en) 2001-05-17

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39670/97A Ceased AU733621B2 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (xx)
JP (1) JP2001509787A (xx)
KR (1) KR20000029679A (xx)
CN (1) CN1073103C (xx)
AU (1) AU733621B2 (xx)
CA (1) CA2262542A1 (xx)
CZ (1) CZ29799A3 (xx)
EE (1) EE9900036A (xx)
FI (1) FI990171A (xx)
HU (1) HUP0003267A3 (xx)
LV (1) LV12291B (xx)
NO (1) NO990433L (xx)
NZ (1) NZ333713A (xx)
PL (1) PL331465A1 (xx)
SI (1) SI9720047A (xx)
SK (1) SK8599A3 (xx)
WO (1) WO1998004537A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502850A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
WO2000014097A2 (de) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyranosen
US6673786B1 (en) 1999-08-10 2004-01-06 Altana Pharma Ag Tryptase inhibitors
JP2003509417A (ja) * 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7015325B2 (en) * 1999-12-20 2006-03-21 Altana Pharma Ag Tryptase inhibitors
TR200402164T4 (tr) 1999-12-20 2004-10-21 Altana Pharma Ag Triptaz inhibitörler
CA2438594A1 (en) * 2001-01-31 2002-08-08 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
CA2438685A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
KR20040016882A (ko) 2001-06-11 2004-02-25 제노포트 인코포레이티드 감소된 독성을 가진 ｇａｂａ 유사체 프로드러그의 구강투여용 투여 형태물
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE348803T1 (de) 2001-06-19 2007-01-15 Altana Pharma Ag Tryptase-inhibitoren
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
CN102159201A (zh) * 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
AU2018266393A1 (en) * 2017-05-12 2019-12-19 Riken Class A GPCR-binding compound modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
UA42719C2 (uk) * 1993-03-12 2001-11-15 Аксіз Фармасьютікелз, Інк Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
JPH10501238A (ja) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション 肥満細胞媒介症状を治療するための組成物及び方法
EP0782571A1 (en) * 1994-09-23 1997-07-09 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
JPH11503417A (ja) * 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション 可逆的プロテアーゼインヒビター
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
LV12291B (en) 2000-04-20
KR20000029679A (ko) 2000-05-25
FI990171A0 (fi) 1999-01-29
CZ29799A3 (cs) 1999-06-16
NZ333713A (en) 2000-12-22
CN1073103C (zh) 2001-10-17
AU3967097A (en) 1998-02-20
PL331465A1 (en) 1999-07-19
NO990433L (no) 1999-03-25
FI990171A (fi) 1999-03-23
CA2262542A1 (en) 1998-02-05
EE9900036A (et) 1999-08-16
EP0934293A1 (en) 1999-08-11
SK8599A3 (en) 2000-03-13
HUP0003267A2 (hu) 2001-06-28
NO990433D0 (no) 1999-01-29
WO1998004537A1 (en) 1998-02-05
JP2001509787A (ja) 2001-07-24
HUP0003267A3 (en) 2002-02-28
LV12291A (lv) 1999-06-20
SI9720047A (sl) 1999-08-31
CN1226892A (zh) 1999-08-25

Similar Documents

Publication Publication Date Title
AU733621B2 (en) Novel compounds and compositions for treating diseases associated with tryptase activity
FI96202C (fi) Menetelmä valmistaa farmakologisesti arvokasta substituoitua aminokarbonyylioksipropionyyli-histidyyliaminoalkoholiyhdistettä
CZ87097A3 (en) Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells
WO2000027826A1 (de) Neue pyrimidine, deren herstellung und verwendung
US5574042A (en) Imidazo [1,2-a] pyridines and their pharmaceutical use
EP0224919A2 (en) New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US6489327B1 (en) Tryptase inhibitors
AU752064B2 (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
EP1057815B1 (en) Cyclic amide compounds
WO2000014097A2 (de) Neue pyranosen
US7015325B2 (en) Tryptase inhibitors
US6562854B2 (en) Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
NZ506614A (en) Compounds for treating diseases associated with tryptase activity
US20030073720A1 (en) Tryptase inhibitors
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
EP1208089A2 (en) Diazocin-dione derivatives and their use as tryptase inhibitors
JPH07330777A (ja) チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
EP1368317B1 (en) Tryptase inhibitors
LV12458B (xx) Savienojums un farmaceitiskās kompozīcijas ar triptāzes aktivitātes izmaiņām saistītu slimību ārstēšanai
AU2002253035A1 (en) Tryptase inhibitors
US20040087792A1 (en) Tryptase-inhibitors
JP2005535685A (ja) トリプターゼ阻害剤としてのピロリジン誘導体
MXPA01009241A (en) Novel compounds and compositions as protease inhibitors

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AXYS PHARMACEUTICALS, INC.

Free format text: FORMER NAME: ARRIS PHARMACEUTICAL CORPORATION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired